- ESMO Immuno-Oncology Congress 2019
- ESMO Preceptorship on Immuno-Oncology 2019: Singapore
- Five-Year Survival Data in Advanced NSCLC Treated with Pembrolizumab
- ESMO Immuno-Oncology Congress 2019: Abstracts
- IMMUNOTARGET Registry in Advanced NSCLC With Oncogenic Driver Alterations
- ESMO Immuno-Oncology Congress 2019: Programme
- First-line Durvalumab Improves Survival Compared to Chemotherapy in Metastatic NSCLC
- Maintenance immunotherapy fails to improve survival in extensive small cell lung cancer [ELCC Press Release]
- PROs Were Consistent with the ITT Population Across PD-L1 Subgroups in Patients with Stage III NSCLC Receiving Durvalumab or Placebo
- Studies give new insights on immunotherapy in elderly patients with advanced NSCLC [ELCC Press Release]
- The Lung Immune Prognostic Index Significantly Associates with Outcome Across a Cancer Patient Population
- Rare Cancers a Growing Focus of Early-stage Clinical Trials [ESMO Press Release]
- FDA Approves Pembrolizumab for Adjuvant Treatment of Melanoma
- TAT International Congress 2019: the home of phase I oncology [ESMO Media Alert]
- Cancer Drug Development Award Given to Geoffrey Shapiro [ESMO Press Release]
- Anticancer Vaccines Gain new Lease of Life with Personalisation Techniques [ESMO Press Release]
- Data from the OAK Trial Show Fast Progression Is Not More Common with Atezolizumab
- Pembrolizumab Improves Long-term Overall Survival over Docetaxel in Advanced NSCLC
- Neoadjuvant Ipilimumab plus Nivolumab Demonstrates Promising Overall Survival and Relapse-free Survival in Stage III Melanoma
- Proton Pump Inhibitor Therapy Negatively Impacts the Efficacy of Nivolumab Plus Ipilimumab Combination Treatment in Melanoma
- Second-Line Nivolumab Is Not Superior to Chemotherapy in SCLC
- First Line Immunotherapy Combination Fails to Improve Overall Survival in Lung Cancer [ESMO Press Release]
- ESMO Immuno-Oncology Congress 2018
- ESMO Immuno-Oncology Congress Showcases New Technologies Set to Improve Cancer Treatment [ESMO Press Release]
- Immuno-Oncology Technology (IOTECH)